Substituted pyridinones

US7067540B2 · kind B2 · utility

Assignee

• Pharmacia Corporation · SE

Inventors

• Balekudru Devadas · Chesterfield, US
• John Walker · Maryland Heights, US
• Shaun Raj Selness · Chesterfield, US
• Terri Boehm · Ballwin, US
• Richard C. Durley · Chesterfield, US
• Rajesh Devraj · Chesterfield, US
• Brian S. Hickory · Wildwood, US
• Paul V. Rucker · Carlsbad, US
• Kevin D. Jerome · Holden, US
• Heather Madsen · University City, US
• Edgardo Alvira · Chesterfield, US
• Michele A. Promo · Maryland Heights, US
• Radhika Blevis-Bal · Chesterfield, US
• Laura Marruto · Ellisville, US
• Jeff Hitchcock · Saint Peters, US
• Thomas Owen · Chesterfield, US
• Win Naing · Chesterfield, US
• Li Xing · Lexington, US
• Huey Shieh · Chesterfield, US
• Aruna Sambandam · Delmar, US
• Shuang Liu · Schenectady, US
• Ian L. Scott · Monroe, US
• Kevin F. McGee, Jr. · Guilderland, US

Key dates

• Filing date: Feb 14, 2003
• Grant date: Jun 27, 2006
• Expiry date: Dec 25, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.